Topic: 【ANN】【ICO】ClinTex CTi - Faster, Cheaper, Safer Medicine : DLT in Clinical Trials - page 8. (Read 5860 times)

It's a unique project in the blockchain field, so I think we'll definitely see something interesting and useful!

The ClintexCTi (Clinical Trials Intelligence) all-in-one data management and analytics solution was designed specifically to deal with the known problem of data integration. The ClintexCTi solution, with its seven connected applications, uses a permissioned consortium blockchain to enable secure and private collaboration and analysis both within and between clinical trial studies. This will allow clinical trial sponsors for the first time to analyze data across the complete range of metrics. By integrating that data, the true potential of a data analytics engine is finally unleashed.

Good luck to project! Hope blockchain economy in game will be good, and we will see something interesting.

The next decade is going to be quite interesting in technology, when inefficiencies that currently cost huge sums of money will be eliminated thanks to blockchain solutions like ClinTex!

Did you know that the Global Drug Development market is worth over $350 billion per annum and there is currently no competitor product where data analytics and machine learning are used to monitor and control clinical trial costs? 🙂 CTi, Clinical Trials Intelligence will bring down the cost of medicine and increase the speed to market and access to new medicines for people who need it, by vastly reducing development costs for the global pharmaceutical industry. ClinTex will be at the forefront of this paradigm shift!  

ClinTex is aiming to transform the clinical trial process and experience to get the best results The Pre-Sale is planned to commence in Q4, 2018. Just follow the project on Telegram to get all the updates https://t.me/ClinTexCTi and https://t.me/ClinTexCTiNews

The project in medical shpere. The idea is good. Soon it will be pre-sale and we will see the results.

There are 4 phases in the current clinical trials. In the first phase of a clinical trial, the proposed drug safety is tested  1/1 and those tests last for more than two months and usually involve a number of healthy volunteers who are paid to be
part of the trial. The aim of this study is to observe how would the human body react to the tested drug or device  and different dosages and intensity are included. The statistics showed the 70% of drugs/devices pass this phase.

The second phase tests the efficiency of the drug/device and usually lasts from several months to about two years.  The number of volunteers in this phase jumps to hundreds of people. Many of the studies conducted in this phase are  random and they are usually applied on two groups of people. The first group takes a dosage of the experimental  drug while the other group takes a standard medication while thinking that they're taking the actual experimental drug.  The researchers are unaware of the actual experiment too. This is done to observe the psychological effects and  human behavior. By gathering this information, the investigators deliver comparative information about the safety and  efficiency of the drug or device to pharmaceutical companies and the FDA. About 33.3% of the tested drugs or  devices go through phase I and II.

The third phase of clinical trials are randomized as well and they usually have several hundred to thousands of  volunteers. In this phase the scale of the testing is way bigger and testing a drug or device would take a minimum of  2 years or even more. By having a large number of volunteers, the investigators get a better understanding and more  details on the effectiveness, benefits, and the possible harmful or unwanted reactions. When a drug/device passes this  phase, pharmaceutical companies are able to request approval from the FDA to start marketing the drug.

The fourth phase and the last phase is named Post Marketing Surveillance Trial which is a study that starts after the  drug or the device is available for consumer use. There are three main objectives of this study, first pharmaceutical  companies compare the new drug or device to other existing drugs. Secondly, they observe the long-term effectiveness  of the drug on the patient's progress and life quality. Third, they determine the cost-effectiveness of the new drug  compared to existing or popular drugs. The results of this phase can lead to having the new drug or device taken off  the market, or some restrictions may apply when using the new medicine or tool.

The cost of running these clinical trials is now higher than ever, with expenses running at between $30 million and $70 million for a single Phase III trial.

Integrating Blockchain technology with Clinical trials will give the following benefits:

1: Security to the clinical data and protection from any alteration 

2: An immutable record that will show data and all changes in a consistent matter   

3: Past data that will show the complete history of clinical information

4: peer-2peer payments via smart contracts

5: Operation interoperability between several systems and data formats

6: Protection of privacy is possible. Blockchain technology allows adding and verifying records to an immutable ledger  without compromising the content of each record. 

7: Control of access to the content of each record by using encryption keys. The public key shows that the record  exists while the private key gives access to the content of the record.

With its revolutionary vision, ClinTex will change how clinical trials occur and usher in a new era of efficiency, speed and accuracy, making medication affordable again.

Visit https://www.clintex.io/

Did you know that CTi will use ChainLink as its decentralised oracle provider?

CTi will utilise oracles to facilitate the triggering of payments within the CTi platform in cases where it is based off of data or occurrences on pharmaceutical source systems that are external to the CTi blockchain network.

ChainLink is the world’s first decentralised oracle network that allows smart contracts to access key offchain resources like data feeds, web APIs, traditional payments and in our case, pharmaceutical source systems.

Here are some other social media platforms where you can follow the team:


Medium blog: https://medium.com/clintexcti
Reddit: https://www.reddit.com/r/ClinTexCTi
Twitter: https://twitter.com/ClinTexCTi
Instagram: https://www.instagram.com/clintex.cti/
Linkedin: https://www.linkedin.com/company/eclintex-ltd
YouTube: https://bit.ly/2B7u34L

Which platform is your favorite to get the latest updates from crypto projects you like?

Hi there

Not sure what you are referring to here? The bitcointalk thread or a listing somewhere? 

At the moment your project is unrated (N/A). You can edit your Page by adding more information about your ICO after verification and also verify team members.

If you've got yourself some time, do take a look at this review of the Clintex Clinical Blockchain Project and their TGE

Link: https://www.coinannouncer.com/a-review-of-the-clintex-clinical-blockchain-project-and-the-tge/

Having a deflationary model like that is pretty awesome. Goes a long way to increase token value over time.

In cases where a client of the ClinTex subsidiary allows a licence to expire, 25% of their staked tokens will be destroyed permanently before the rest are returned to the circulating supply. This will be part of the contract the pharmaceutical client signs with ClinTex, and the token burn will be verifiable by smart contract.

The CLX token will be used to purchase the licence for access to CTi, by staking the users balance in the CTi integrated wallet for the period of the licence.

CLX has a secondary utility of inter-platform payments to data providers and clinical sites.

Check out the technical paper if you haven't: https://clintex.io/Clintex_CTi_Techpaper.pdf

No confirmed date yet, but it'll take place in Q4 2018 so in a few months

Next month I think